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Objective: We postulated that either oral or vaginal administration of the immune response modifier imiquimod
woulddecreasevaginalsheddingofChlamydiatrachomatis,mousepneumonitisstrain(MoPn),inamurinemodel.
Methods: Female BALB/c mice were infected intravaginally with C. trachomatis (MoPn) and were administered
imiquimodeitherorally(30 mg/kg)orvaginally(10 µlof5%imiquimodcream)priortoinfectionandeverysecond
day after infection for a total of four doses. The course of infection was monitored by collecting cervical–vaginal
swabs and isolation in HeLa 229 cell culture. To determine whether the drug affected T helper type 1 or T helper
type2immuneresponsepolarization,immunoglobulinG(IgG)subclassantibodyresponseswereassessedatday56
after infection.
Results: There was no significant difference in the course of infection when imiquimod-treated mice were
compared with sham-treated controls, regardless of whether the drug was administered orally or vaginally. IgG
subclass antibody responses, and by extension, T helper type 1 to T helper type 2 immune response polarization,
were also unaffected.
Conclusions: Imiquimod has no efficacy in controlling C. trachomatis (MoPn) infection in the murine model.
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Imiquimod (Aldara, R-837, S-26308), an
imidazoquinolinamine, is a proven immune
response modifier that induces endogenous cyto-
kine secretion from monocytes or macrophages
(e.g. interferon-α, interferon-γ, tumor necrosis
factor-α, interleukin (IL)-1β, and IL-6, IL-8 and
IL-12), and similarly elicits interferon-α and IL-6
from epithelial cells1–3. It also enhances antigen
presentation by dendritic cells and the expression
oftheinducibleformofnitricoxidesynthase.Thus
the cytokine milieu that is generated by
imiquimod is thought to lead to type 1T helper
cell (Th1) dominance and enhanced cell-mediated
immunity3. In mice, cell-mediated immunity and
Th1cytokine polarization of an immune response
are known to influence the isotype switch of
B-cells toward the production of immunoglobulin
G2a (IgG2a) antibodies such that a surrogate
marker for a Th1polarized immune response is
predominance of IgG2a production4.
Clinically, imiquimod is approved for the
topicaltreatmentofgenitalwartscausedbyhuman
papilloma virus (HPV) infections. However, it
also has demonstrated efficacy in humans and
in animal models for the treatment of non-
genital warts and mollusca5,6, herpes simplex
virus (HSV)7–11, cytomegalovirus12 and cancerous
lesions, including initial squamous-cell and
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 2003 The Parthenon Publishing Group 81basal-cell carcinoma in immunocompetent and
immunosuppressed patients2. Recent studies have
also shown efficacy for imiquimod in the treat-
ment of experimental murine and drug-resistant
human cutaneous leishmaniasis13,14. In each
instance, imiquimod is thought to exert its effect
through the induction of interferons and certain
other cytokines that enhance Th1 responses15.
Immunity to chlamydial infections in humans
is not well defined, but probably involves a
contribution of both local antibody production
and T-cell responses16. In vitro, the effect of
interferon-γ on the restriction of intracellular rep-
lication of Chlamydia in human epithelial cells is
particularly well characterized17. Although they
have not yet been fully defined, protective
immune mechanisms have been better character-
ized in murine models where a Th1polarized
response is of central importance18. Briefly, resolu-
tion of C. trachomatis infection in the mouse is
known to require major histocompatibility com-
plex (MHC) class II antigen processing by den-
dritic cells and the subsequent activation of T-cells
that produce interferon-γ to migrate to the site of
infection19–26. A similar dependence on T-cells is
required for the prevention of subsequent infec-
tions, but a role for B-cell-mediated antigen pro-
cessing in eliciting this response appears to be
crucial27,28.
Given the importance of a cell-mediated
immune response in resolving chlamydial infec-
tions, we postulated that chlamydial infection
would be decreased in magnitude or over time by
the administration of imiquimod in a murine
model, and that this would be accomplished by
enhancing a cytokine profile characteristic of that
observed in Th1polarized immune responses.
Alternatively, imiquimod could enhance the local
cytokine milieu (e.g. interferons) at the site of
infection, which would either directly lead to
decreased shedding of C. trachomatis or enhance
Th1 polarization at the onset of the response.
MATERIALS AND METHODS
Infection, infection assessment and experimental
design
Six to eight-week-old BALB/c mice were
purchased from Harlan-Sprague-Dawley
(Indianapolis, IN) and allowed to acclimatize for
one week. Mice were allowed access to food and
water ad libitum. Seven days prior to infection,
mice were pretreated with 2.5 mg of medroxy-
progesterone acetate (DepoProvera, Upjohn,
Kalamazoo, MI) and inoculated intravaginally
with 200 ID50 (104 inclusion-forming units, IFUs)
of C. trachomatis, mouse pneumonitis strain
(MoPn), exactly as described by Cotter and
co-workers26,29. Infection was assessed by collect-
ing cervical–vaginal swabs 4, 7, 10 and 14 days
after infection and weekly thereafter. Culture
of swab-collected material in HeLa 229 cell
monolayers in 24 well plates was performed, and
IFUs were counted by indirect fluorescent anti-
body staining and viewing on an inverted fluores-
cent microscope26. In the first experiment, mice
were administered imiquimod (30 mg/kg sus-
pendedin0.25 mlofsterilesaline)bygavage3days
prior to infection and again on the day of infec-
tion and at 3, 6 and 9 days after infection. Control
mice were administered a similar volume of saline
alone, also by gavage.
Inasecondexperiment,10 µlof5%imiquimod
cream were applied intravaginally using a blunted
small-bore (26-gauge) 5/8th-inch straight gavage
needle on a 0.5-ml syringe at 2 days prior to infec-
tion and again 1, 3 and 6 days after infection.
Cervical–vaginal swabs were collected at identical
time points to those in the first experiment,
thereby avoiding the collection of swabs and
administrationofthedrugonthesamedays,which
could possibly interfere with the sampling method
or with the effect of the drug.
IgG subclass antibody response determination
In order to determine whether the administration
of imiquimod enhanced Th1responses or induced
a shift in Th1to Th2 immune response polariza -
tion,IgGsubclassantibodyresponseswereassessed
using an enzyme-linked immunosorbent assay
(ELISA). Briefly, on the day of infection and 56
days after infection, mice were anesthetized with
pentobarbitalandbloodwascollectedviapuncture
of the retro-orbital venous plexus. Plasma IgG
antibody subclass responses were assessed on
serial two-fold dilutions (beginning with a 1:10
dilution) using a previously published method30.
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phosphatase-labeled rat antibody against mouse
IgG1, IgG2a, IgG2b or IgG3 (Southern
Biotechnology Associates, Birmingham, AL).
Optical densities were read using a Dynatek
MR5000 automated 96-well spectrophotometer
with Biolinks software. After background sub-
traction (of wells receiving secondary antibody
only), an arbitrary cut-off value at an OD405 of
0.1 was considered to be a positive reaction.
Statistical analysis
The course of infection was analyzed by a two-
factor (treatment group and days) repeated-
measures analysis of variance (ANOVA), and
post-hoc analysis was completed using a Tukey–
Kramer test. ELISA titers were analyzed by
converting to an arithmetical scale and comparing
the means using a two-way unpaired t-test.
RESULTS
As shown in Figure 1, the oral administration of
imiquimod did not alter the course of infection as
assessed by shedding of viable C. trachomatis,
MoPn. However, we did observe an effect of
administration of the drug in that mice in the
imiquimod-treated group consistently appeared to
be somewhat morbid as evidenced by a lack of
grooming, a loss of luster of the fur, and more agi-
tation on handling. Similar changes were not
observed in the mice that were treated with saline
only. In order to determine whether the adminis-
tration of imiquimod enhanced the Th1response
or otherwise affected the Th1to Th2 polarization,
IgG subclass antibody responses were assessed
using ELISA. Antibody levels on day 0 were con-
sistently below the detectable range at the lowest
dilution assessed (1:10; data not shown). As shown
inFigure2,bothgroupsdisplayedanIgGantibody
subclass profile indicative of a vigorous Th1
response (IgG2a predominating over IgG1)4.N o
change in the overall antibody response of any IgG
subclass was affected by imiquimod treatment.
This indicated that the drug did not induce a shift
in Th1to Th2 immune response polarization as
measured by this method, nor was an enhanced
Th1 response evident.
One explanation for the lack of effect of
imiquimod in our first experiment could be that
we used a systemic route for administration of
the drug, whereas the infection in its earliest stages
islocalizedtothegenitalepithelium.Thereforewe
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Figure 1 Shedding of viable C. trachomatis, mouse
pneumonitis strain, following intravaginal inoculation in
mice that were administered imiquimod (n = 47, filled
circles) or saline (n = 49, open circles) by gavage.
Symbols represent the mean inclusion-forming units
(IFU) isolated from cervical–vaginal swabs at each time
point. No differences were observed when the courses
of infection for the two groups were compared by
two-factor (treatment group and days) repeated-
measures analysis of variance (ANOVA) with post-hoc
analysis using a Tukey–Kramer test
Figure 2 Immmunoglobulin G (IgG) subclass antibody
response at day 56 after infection following C.
trachomatis (mouse pneumonitis strain) infection in mice
that were administered imiquimod (n = 7, filled bars) or
saline (n = 6, open bars). Each bar represents the mean
log10 antibody titer for each group. No differences were
observed in any IgG subclass antibody response when
compared using a two-way unpaired t-testrepeated the experiment using a local, topically
applied preparation of imiquimod (Aldara, 5%
imiquimod cream). The experiment was of similar
design to the previous one except that 10 µlo f
5% imiquimod cream were applied intravaginally
as described in the Materials and Methods section.
As in the first experiment, blood was collected
on the day of infection and again at 56 days after
infection.
Figure 3 shows that vaginal application of
5% imiquimod cream did not alter the course of
infection. Furthermore, as shown in Figure 4,
administrationofimiquimodintravaginallydidnot
induce a shift in the Th1to Th2 immune response
as indicated by a change in the IgG antibody sub-
classresponses.Asobservedinthefirstexperiment,
background levels of antibody in all IgG subclasses
remained below detectable levels (data not
shown). Interestingly, in this experiment we con-
sistently detected a low IgG1response in both
groups of mice, which may indicate a slight shift
toward a type-2 response phenotype. This
response was also observed in the vehicle-only
treatment group, indicating that the effect may be
duetoalteredantigenpenetrationandpresentation
at the site of infection due to the vehicle. How-
ever, this is not at all conclusive, because the IgG1
responses were not compared in a protocol where
oral and vaginal administration of imiquimod
were compared in the same experiment.
DISCUSSION
Our results indicate that imiquimod affected
neither resolution of chlamydial genital infec-
tion in this model nor reduced shedding of
C. trachomatis (MoPn), whether administered
locally at the site of infection or systemically via
the oral route. This drug also does not induce an
obvious shift in IgG antibody subclass responses
that would by extension indicate either an
enhanced Th1response or a significant shift
toward Th2 polarization in response to the infec-
tion in this model.
Although these results do not hold promise for
imiquimodintherapyforchlamydialinfection,we
cannotruleoutthepossibilityofitsusetoassessthe
immune response in certain other aspects of
the infection. For example, in the context of this
study, we did not assess pathological outcome sub-
sequent to infection resolution. It is possible that
although the drug did not alter the course of
infection, chronic sequelae such as infertility31 and
hydrosalpinx32,33 formation might be affected by
host responses that were induced by the drug but
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Figure 3 Shedding of viable C. trachomatis, mouse
pneumonitis strain, following intravaginal inoculation in
mice that were administered imiquimod (n = 10, filled
circles) or vehicle only (n = 10, open circles) intra-
vaginally. Symbols represent the mean IFU isolated from
cervical–vaginal swabs at each time point. No differences
were observed when the courses of infection for the
two groups were compared by two-factor (treatment
group and days) repeated-measures ANOVA with
post-hoc analysis using a Tukey–Kramer test
Figure 4 IgG subclass antibody response at day 56
after infection following C. trachomatis (mouse pneumo-
nitis strain) infection in mice that were administered
imiquimod (n = 5, filled bars) or vehicle only (n = 5,
open bars). Each bar represents the mean log10 antibody
titer for each group. No differences were observed in
any IgG subclass antibody response when compared
using a two-way unpaired t-testnot measured in our study. In addition, although
neither a distinct shift from Th1to Th2 polariza -
tion nor an enhancement of the natural Th1
response was observed, it is possible that any effect
of the drug in this regard was masked due to
the obvious potent Th1response that develops
naturally in response to this infection. This was
evidenced by the high level of IgG2a production
illustrated in Figures 2 and 4, and it has been
reported elsewhere34. Although we chose the
BALB/c strain of mice due to the fact that they are
characterized as being moderately susceptible in
this model, they do show many features of a Th1
response. Perhaps an effect would have been
observed in a more susceptible strain, such as the
C3H/HeN18. Thus alteration of a naturally potent
Th1responseorovercomingthegeneticcomposi-
tion of the host by chemical manipulation may
prove difficult. A final explanation for the lack of
effectofimiquimodinthismodelmayrelatetothe
actual mode of action of this drug. It has recently
been shown that in mice imiquimod acts through
the Toll-like-receptor-7 (TLR7)-MyD88-
dependent signaling pathway34. Although these
receptors are known to be expressed in certain
leukocyte populations, their anatomic distribution
within the mouse has not yet been described in
detail. Thus if TLR7-MyD88 receptors are not
expressed in sufficient quantities in the mouse in
the genital epithelium or in tissues immediately
adjacent to the latter, the lack of an adequate local
target for the drug may explain its lack of effect
in this model.
Kelly et al.35 found that the route of exposure
to viable C. trachomatis (MoPn) determined the
type of response profile that was elicited. They
found that subcutaneous administration of viable
C. trachomatis (MoPn), yielded a predominant Th2
response, whereas administration by mucosal
routes (oral, intranasal and vaginal) yielded a pre-
dominant Th1polarization. Thus although an
effect of imiquimod on infection and immune
response was not observed, this drug might yet
provetohaveefficacyinalteringimmuneresponse
profiles subsequent to artificial immunization
against chlamydial antigen by other routes. This
may be particularly likely if it is found that
TLR7-MyD88 expression densities vary between
tissues as described above.
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